Skip to content

Released Aug 5, 2024, after the close

10-Q filed Aug 5, 2024, 36 days after period end · 0000950170-24-090782

Q2 2024 · 10-Q
Revenue$114.00K−57.6% vs Q2 2023−18.6% vs Q1 2024
Net Income-$17.86MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.33N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$19,061,000N/M
Operating Cash Flowderived-$18,744,000N/M
Margins · derived
Operating margin-16720.2%−11928.4 pt vs Q2 2023
Net margin-15668.4%−11244.6 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$114.00K$269.00K$896.00K$2.11M
Net Income-$17.86M-$11.90M-$28.70M-$18.60M
EPS Diluted-$0.33-$0.23-$0.87-$0.63

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR